Analysts Expect TherapeuticsMD, Inc. (TXMD) Will Post Quarterly Sales of $4.69 Million

Equities research analysts predict that TherapeuticsMD, Inc. (NASDAQ:TXMD) will report sales of $4.69 million for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for TherapeuticsMD’s earnings. The highest sales estimate is $5.50 million and the lowest is $4.00 million. TherapeuticsMD reported sales of $4.49 million during the same quarter last year, which would suggest a positive year over year growth rate of 4.5%. The firm is scheduled to announce its next earnings report on Thursday, February 22nd.

According to Zacks, analysts expect that TherapeuticsMD will report full-year sales of $4.69 million for the current year, with estimates ranging from $16.70 million to $18.15 million. For the next year, analysts anticipate that the business will report sales of $40.46 million per share, with estimates ranging from $25.68 million to $74.22 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow TherapeuticsMD.

TherapeuticsMD (NASDAQ:TXMD) last posted its earnings results on Monday, November 6th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.03. The firm had revenue of $4.42 million during the quarter, compared to the consensus estimate of $5.36 million. TherapeuticsMD had a negative return on equity of 65.16% and a negative net margin of 457.00%. The business’s quarterly revenue was down 19.7% on a year-over-year basis. During the same period last year, the company earned ($0.13) earnings per share.

TXMD has been the subject of several recent research reports. BidaskClub raised TherapeuticsMD from a “strong sell” rating to a “sell” rating in a research note on Wednesday, October 25th. Cantor Fitzgerald reissued a “buy” rating and issued a $28.00 price target on shares of TherapeuticsMD in a research note on Sunday, January 7th. Zacks Investment Research cut TherapeuticsMD from a “hold” rating to a “sell” rating in a research note on Friday, January 12th. Noble Financial reissued a “buy” rating on shares of TherapeuticsMD in a research note on Thursday, November 30th. Finally, Oppenheimer set a $10.00 price target on TherapeuticsMD and gave the company a “buy” rating in a research note on Monday, October 16th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $14.50.

In other TherapeuticsMD news, Director Tommy G. Thompson bought 5,000 shares of the firm’s stock in a transaction that occurred on Friday, December 8th. The stock was acquired at an average price of $6.21 per share, with a total value of $31,050.00. Following the completion of the purchase, the director now directly owns 3,555 shares of the company’s stock, valued at approximately $22,076.55. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 23.92% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Edge Wealth Management LLC grew its stake in TherapeuticsMD by 2,500.0% during the fourth quarter. Edge Wealth Management LLC now owns 20,800 shares of the company’s stock worth $125,000 after purchasing an additional 20,000 shares during the period. Schwab Charles Investment Management Inc. grew its stake in TherapeuticsMD by 18.4% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 819,043 shares of the company’s stock worth $4,948,000 after purchasing an additional 127,410 shares during the period. GSA Capital Partners LLP acquired a new stake in TherapeuticsMD during the third quarter worth approximately $528,000. Bamco Inc. NY grew its stake in TherapeuticsMD by 8.2% during the third quarter. Bamco Inc. NY now owns 920,000 shares of the company’s stock worth $4,867,000 after purchasing an additional 70,000 shares during the period. Finally, Alyeska Investment Group L.P. acquired a new stake in TherapeuticsMD during the third quarter worth approximately $2,812,000. 73.78% of the stock is owned by institutional investors and hedge funds.

TherapeuticsMD (TXMD) traded up $0.17 during trading on Monday, reaching $6.47. The company’s stock had a trading volume of 1,580,000 shares, compared to its average volume of 2,440,000. The company has a market capitalization of $1,400.00, a P/E ratio of -16.59 and a beta of 1.06. TherapeuticsMD has a 1 year low of $3.50 and a 1 year high of $8.30.

COPYRIGHT VIOLATION WARNING: This article was first reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/01/22/analysts-expect-therapeuticsmd-inc-txmd-will-post-quarterly-sales-of-4-69-million.html.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Get a free copy of the Zacks research report on TherapeuticsMD (TXMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply